[Form 4] BRISTOL MYERS SQUIBB CO Insider Trading Activity

Rhea-AI Filing Summary

Bristol Myers Squibb (BMY) reported insider equity activity by EVP, Chief Supply Chain & Ops, Karin Shanahan. On 11/01/2025, 6,281 restricted stock units converted into common stock at $0 (code M). To cover taxes, 3,213 shares were withheld at $46.07 (code F).

Following these transactions, direct holdings were 16,865 shares, with an additional 1,278.692 shares held indirectly via the BMS Savings and Investment Program. Outstanding awards included 12,562 restricted stock units after the event. The RSU grant vests in three equal annual installments beginning on November 1, 2025, with each unit converting into one share upon vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shanahan Karin

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NJ 08543

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Supply Chain & Ops

3. Date of Earliest Transaction (Month/Day/Year)
11/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.10 par value	11/01/2025		M		6,281(1)	A	$0	20,078	D
Common Stock, $0.10 par value	11/01/2025		F		3,213(2)	D	$46.07	16,865	D
Common Stock, $0.10 par value								1,278.692(3)	I	BMS Savings and Investment Program

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	11/01/2025		M			6,281	(5)	11/01/2027	Common Stock, $0.10 par value	6,281	$0	12,562	D

Explanation of Responses:

1. Represents vesting of one-third of restricted stock units granted on November 1, 2024.

2. Shares withheld for payment of taxes upon vesting of awards.

3. Based on recent 401(k) plan statement.

4. Each restricted stock unit converts into one share of common stock upon vesting.

5. The restricted stock units vest in three equal annual installments beginning on November 1, 2025.

Remarks:

	/s/ Lisa A. Atkins, attorney-in-fact for Karin Shanahan	11/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BMY disclose on this Form 4?

An executive reported 6,281 RSUs converting to common stock at $0 and the withholding of 3,213 shares at $46.07 for taxes on 11/01/2025.

How many BMY shares does the reporting person hold after the transactions?

Direct holdings are 16,865 shares, plus 1,278.692 shares held indirectly via the BMS Savings and Investment Program.

How many restricted stock units remain outstanding for the BMY executive?

After the reported event, 12,562 RSUs remained outstanding.

What do the transaction codes M and F indicate on the BMY Form 4?

Code M reflects conversion of RSUs to common stock; code F reflects share withholding to satisfy tax obligations.

When do the BMY restricted stock units vest?

They vest in three equal annual installments beginning on November 1, 2025, and convert into one share each upon vesting.

Who is the reporting person in this BMY filing and what is their role?

The reporting person is Karin Shanahan, EVP, Chief Supply Chain & Ops at Bristol Myers Squibb.